Dexiao Kong

247 Beiyuan Road
Jinan, 250033, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study.

Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study.

Journal: Blood cancer journal
Published: May 04, 2026

IL-1Ra overexpression enhances the therapeutic efficacy of mesenchymal stem cells in acute lung injury.

IL-1Ra overexpression enhances the therapeutic efficacy of mesenchymal stem cells in acute lung injury.

Journal: International immunopharmacology
Published: April 27, 2026

Therapeutic outcomes of TP53-mutated diffuse large B cell lymphoma: A systematic review and meta-analysis.

Therapeutic outcomes of TP53-mutated diffuse large B cell lymphoma: A systematic review and meta-analysis.

Journal: iScience
Published: March 10, 2026

DKC1: a robust prognostic factor and potential therapeutic target in multiple myeloma.

DKC1: a robust prognostic factor and potential therapeutic target in multiple myeloma.

Journal: Journal of translational medicine
Published: November 13, 2025

AMP-36 exhibits potent therapeutic efficacy against MRSA pneumonia through membrane-target mechanism.

AMP-36 exhibits potent therapeutic efficacy against MRSA pneumonia through membrane-target mechanism.

Journal: Scientific reports
Published: November 10, 2025

Organoids for disease modeling and treatment: state-of-the-art.

Organoids for disease modeling and treatment: state-of-the-art.

Journal: Experimental hematology & oncology
Published: August 31, 2025

Correction: Interleukin-1 receptor antagonist overexpression in mesenchymal stem cells improves hemorrhagic cystitis outcomes via HtrA serine peptidase 3.

Correction: Interleukin-1 receptor antagonist overexpression in mesenchymal stem cells improves hemorrhagic cystitis outcomes via HtrA serine peptidase 3.

Journal: Stem cell research & therapy
Published: July 07, 2025

The silent players: Atypical BCR‑ABL isoforms as biomarkers and therapeutic hurdles in CML pathogenesis (Review).

The silent players: Atypical BCR‑ABL isoforms as biomarkers and therapeutic hurdles in CML pathogenesis (Review).

Journal: Oncology reports
Published: May 28, 2025

Targeted inhibition of ITK activity with anti-CD3 antibody-modified calcium silicate nanoparticles loaded with novel 7H-Pyrrolo[2,3-d]pyrimidine derivatives for treating aplastic anemia.

Targeted inhibition of ITK activity with anti-CD3 antibody-modified calcium silicate nanoparticles loaded with novel 7H-Pyrrolo[2,3-d]pyrimidine derivatives for treating aplastic anemia.

Journal: Journal of nanobiotechnology
Published: May 15, 2025

Interleukin-1 receptor antagonist overexpression in mesenchymal stem cells improves hemorrhagic cystitis outcomes via HtrA serine peptidase 3.

Interleukin-1 receptor antagonist overexpression in mesenchymal stem cells improves hemorrhagic cystitis outcomes via HtrA serine peptidase 3.

Journal: Stem cell research & therapy
Published: February 05, 2025

Uncovering the cellular and omics characteristics of natural killer cells in the bone marrow microenvironment of patients with acute myeloid leukemia.

Uncovering the cellular and omics characteristics of natural killer cells in the bone marrow microenvironment of patients with acute myeloid leukemia.

Journal: Cancer cell international
Published: December 26, 2023

Annexin A1: a key regulator of T cell function and bone marrow adiposity in aplastic anaemia.

Annexin A1: a key regulator of T cell function and bone marrow adiposity in aplastic anaemia.

Journal: The Journal of physiology
Published: December 15, 2023
Showing 1-12 of 21

Last Updated: 09/26/2026